Clinical laboratory evaluation of potential reduced exposure products for smokers

Nicotine and Tobacco Research

Volumn 8, Issue 6, 2006, Pages 727-738

  Breland, Alison B ^a   Kleykamp, Bethea A ^a   Eissenberg, Thomas ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARBON MONOXIDE; CARCINOGEN; NICOTINE; NITROSAMINE; POLYCYCLIC AROMATIC HYDROCARBON;

ADULT; ARTICLE; CANCER; CIGARETTE SMOKING; CLINICAL LABORATORY; EXPOSURE; HUMAN; MALE; MORTALITY; PRIORITY JOURNAL; RELAPSE; SMOKING CESSATION; UNITED STATES; URINALYSIS; WITHDRAWAL SYNDROME;

ADULT; BIOLOGICAL MARKERS; CARBON MONOXIDE; CARCINOGENS; COTININE; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINE; NITROSAMINES; RESPIRATORY FUNCTION TESTS; SMOKING; SMOKING CESSATION; SUBSTANCE WITHDRAWAL SYNDROME; TOBACCO USE DISORDER;

EID: 33751555622     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1080/14622200600789585     Document Type: Article

References (46)

1. Acosta, M. C. and Buchhalter, A. R. and Breland, A. B. and Hamilton, D. and Eissenberg, T. (2004) Urine cotinine as an index of smoking status in smokers during 96-hour abstinence: Comparison of GC/MS with immunoassay test strips. Nicotine & Tobacco Research, 6, pp. 1-6.
2. Baldinger, B. and Hasenfratz, M. and Battig, K. (1995) Switching to ultralow nicotine cigarettes: Effects of different tar yields and blocking of olfactory cues. Pharmacology, Biochemistry, and Behavior, 50, pp. 233-239.
3. Breland, A. B. and Acosta, M. C. and Eissenberg, T. (2003) Tobacco-specific nitrosamines and potential reduced exposure products for smokers: A preliminary evaluation of Advance. Tobacco Control, 12, pp. 317-321.
4. Breland, A. B. and Buchhalter, A. R. and Evans, S. E. and Eissenberg, T. (2002) Evaluating acute effects of potential reduced exposure products for smokers: Clinical laboratory methodology. Nicotine & Tobacco Research, 4((Suppl.)), pp. S131-S140.
5. Breland, A. B. and Evans, S. E. and Buchhalter, A. R. and Eissenberg, T. (2002) Acute effects of Advance: A potential reduced exposure product for smokers. Tobacco Control, 11, pp. 376-378.
6. Brown, B. and Kolesar, J. and Lindberg, K. and Meckley, D. and Mosberg, A. and Doolittle, D. (1998) Comparative studies of DNA adduct formation in mice following dermal application of smoke condensates from cigarettes that burn or primarily heat tobacco. Mutation Research, 414, pp. 21-30.
7. Brzeznicki, S. and Jakubowski, M. and Czerski, B. (1997) Elimination of 1-hydroxypyrene after human volunteer exposure to polycyclic aromatic hydrocarbons. International Archives of Occupational and Environmental Health, 70, pp. 257-260.
8. Buchet, J. P. and Gennart, J. P. and Mercado-Calderon, F. and Delavignette, J. P. and Cupers, L. and Lauwerys, R. (1992) Evaluation of exposure to polycyclic aromatic hydrocarbons in a coke production and a graphite electrode manufacturing plant: Assessment of urinary excretion of 1-hydroxypyrene as a biological indicator of exposure. British Journal of Industrial Medicine, 49, pp. 761-768.
9. Buchhalter, A. R. and Acosta, M. C. and Evans, S. E. and Breland, A. B. and Eissenberg, T. (2005) Tobacco abstinence symptom suppression: The role played by the smoking-related stimuli that are delivered by denicotinized cigarettes. Addiction, 100, pp. 550-559.
10. Buchhalter, A. R. and Schrinel, L. and Eissenberg, T. (2001) Withdrawal-suppressing effects of a novel smoking system: Comparison with own brand, not own brand, and denicotinized cigarettes. Nicotine and Tobacco Research, 3, pp. 111-118.
11. Carmella, S. G. and Akerkar, S. and Richie, J. P., Jr. and Hecht, S. S. (1995) Intraindividual and interindividual differences in metabolites of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in smokers' urine. Cancer Epidemiology, Biomarkers & Prevention, 4, pp. 635-642.
12. Carmella, S. G. and Han, S. and Fristad, A. and Yang, Y. and Hecht, S. S. (2003) Analysis of total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in human urine. Cancer Epidemiology, Biomarkers & Prevention, 12, pp. 1257-1261.
13. Carmella, S. G. and Han, S. and Villalta, P. W. and Hecht, S. S. (In press) Analysis of total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNAL) in smoker's blood. Cancer Epidemiology, Biomarkers & Prevention
14. Carmella, S. G. and Le, K.-A. and Hecht, S. S. (2004) Improved method for determination of 1-hydroxypyrene in human urine. Cancer Epidemiology, Biomarkers & Prevention, 13, pp. 1261-1264.
15. Carmella, S. G. and Ye, M. and Upadhyaya, P. and Hecht, S. S. (1999) Stereochemistry of metabolites of a tobacco-specific lung carcinogen in smokers' urine. Cancer Research, 59, pp. 3602-3605.
16. Cohen, S. and Lichtenstein, E. and Prochaska, J. O. and Rossi, J. S. and Gritz, E. R. and Carr, C. R. and Orleans, C. T. and Schoenbach, V. J. and Biener, L. and Abrams, D. and DiClemente, C. and Curry, S. and Marlatt, G. A. and Cummings, K. M. and Emont, S. L. and Giovino, G. and Ossip-Klein, D. (1989) Debunking myths about self-quitting. American Psychologist, 44, pp. 1355-1365.
17. Doll, R. and Peto, R. and Wheatley, K. and Gray, R. and Sutherland, I. (1994) Mortality in relation to smoking: 40 years' observations on male British doctors. British Medical Journal, 309, pp. 901-911.
18. Eissenberg, T. and Greenwald, M. K. and Johnson, R. E. and Liebson, I. A. and Bigelow, G. E. and Stitzer, M. L. (1996) Buprenorphine's physical dependence potential: Antagonist-precipitated withdrawal in humans. Journal of Pharmacology and Experimental Therapeutics, 276, pp. 449-459.
19. Evans, S. E. and Eissenberg, T. (2004, February). In Do brand-induced changes in puff topography occur outside of the laboratory?. Poster presented at the 10th annual meeting of the Society for Research on Nicotine and Tobacco, Phoenix, AZ
20. Fagerström, K. O. and Hughes, J. R. and Ramussen, T. and Callas, P. W. (2000) Randomised trial investigating effect of a novel nicotine delivery device (Eclipse) and a nicotine oral inhaler on smoking behaviour, nicotine and carbon monoxide exposure, and motivation to quit. Tobacco Control, 9, pp. 327-333.
21. Federal Trade Commission.(2000). In "Tar", nicotine, and carbon monoxide of the smoke of 1294 varieties of domestic cigarettes for the year 1998. Washington DC: Author.
22. Foulds, J. and Stapleton, J. and Feyerabend, C. and Vesey, C. and Jarvis, M. and Russell, M. A. H. (1992) Effects of transdermal nicotine patches on cigarette smoking: A double blind crossover study Psychopharmacology, 106, pp. 421-427.
23. Giovino, G. A. and Tomar, S. L. and Reddy, M. N. and Peddicord, J. P. and Zhu, B.-P. and Eriksen, M. P.(1996) Attitudes, knowledge, and beliefs about low-yield cigarettes among adolescents and adults. National Cancer Institute. In The FTC cigarette test method for determining tar, nicotine, and carbon monoxide yields of U.S. cigarettes: Report of the NCI Expert Committee. Bethesda MD: U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. (Smoking and Tobacco Control Monograph No.7)
24. Gust, S. W. and Pickens, R. W. (1982) Does cigarette nicotine yield affect puff volume? Clinical Pharmacology and Therapeutics, 32, pp. 418-422.
25. Haney, M. and Ward, A. S. and Comer, S. D. and Foltin, R. W. and Fischman, M. W. (1999) Abstinence symptoms following smoking marijuana in humans. Psychopharmacology, 141, pp. 395-404.
26. Hatsukami, D. K. and Giovino, G. A. and Eissenberg, T. and Clark, P. I. and Lawrence, D. and Leischow, S. (2005) Methods to assess potential reduced exposure products. Nicotine & Tobacco Research, 7, pp. 827-844.
27. Hatsukami, D. K. and Hughes, J. R. and Pickens, R. (1985) Characterization of tobacco withdrawal: Physiological and subjective effects. National Institute on Drug Abuse Research Monographs, 53, pp. 56-67.
28. Hatsukami, D. K. and Lemmonds, C. and Zhang, Y. and Murphy, S. E. and Le, C. and Carmella, S. G. and Hecht, S. S. (2004) Evaluation of carcinogen exposure in people who used 'reduced exposure' tobacco products. Journal of the National Cancer Institute, 96, pp. 844-852.
29. Hecht, S. S. (1999) Tobacco smoke carcinogens and lung cancer. Journal of the National Cancer Institute, 91, pp. 1194-1210.
30. Hecht, S. S. and Carmella, S. G. and Chen, M. and Dor Koch, D. F. and Miller, A. T. and Murphy, S. E. and Jensen, J. A. and Zimmerman, C. L. and Hatsukami, D. K. (1999) Quantification of urinary metabolites of a tobacco-specific lung carcinogen after smoking cessation. Cancer Research, 59, pp. 590-596.
31. Hughes, J. R. and Hatsukami, D. (1986) Signs and symptoms of tobacco withdrawal. Archives of General Psychiatry, 43, pp. 289-294.
32. Huynh, H. and Feldt, L. S. (1976) Estimation of the box correction for degrees of freedom from sample data in randomized block and split-plot designs. Journal of Educational Statistics, 1, pp. 69-82.
33. Keppel, G.(1991). In Design and analysis: A researcher's handbook. Englewood Cliffs NJ: Prentice Hall.
34. Lakier, J. B. (1992) Smoking and cardiovascular disease. The American Journal of Medicine, 93, pp. S1-S8.
35. Lee, E. M. and Malson, J. L. and Moolchan, E. T. and Pickworth, W. B. (2004) Quantitative comparisons between a nicotine delivery device (Eclipse) and conventional cigarette smoking. Nicotine & Tobacco Research 6, pp. 95-102.
36. Levin, E. D. and Westman, E. C. and Stein, R. M. and Carnahan, E. and Sanchez, M. and Herman, S. and Behm, F. M. and Rose, J. E. (1994) Nicotine skin patch treatment increases abstinence, decreases withdrawal symptoms, and attenuates rewarding effects of smoking. Journal of Clinical Psychopharmacology, 14, pp. 41-49.
37. McGinnis, J. M. and Foege, W. H. (1993) Actual causes of death in the United States. Journal of the American Medical Association, 270, pp. 2207-2212.
38. Mokdad, A. H. and Marks, J. S. and Stroup, D. F. and Gerberding, J. L. (2004) Actual causes of death in the United States, 2000. The Journal of the American Medical Association, 291, pp. 1238-1245.
39. Naidong, W. and Shou, W. and Chen, Y.L. and Jiang, X. (2001) Novel liquid chromatographic-tandem mass spectrometric methods using silica columns and aqueous-organic mobile phases for quantitative analysis of polar ionic analytes in biological fluids. Journal of Chromatography B, 754, pp. 387-399.
40. National Cancer Institute.(2001, October). In Risks associated with smoking cigarettes with low machine-measured yields of tar and nicotine. Bethesda MD: U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. (Smoking and Tobacco Control Monograph No. 13; NIH Publication No.02-5074)
41. Pickworth, W. B. and Bunker, E. B. and Henningfield, J. E. (1994) Transdermal nicotine: Reduction of smoking with minimal abuse liability. Psychopharmacology, 115, pp. 9-14.
42. (2001). In Clearing the smoke: Assessing the science base for tobacco harm reduction. Washington DC: National Academies Press.
43. Thun, M. J. and Heath, C. W., Jr. (1997) Changes in mortality from smoking in two American Cancer Society prospective studies since 1959. Preventive Medicine, 26, pp. 422-426.
44. Tiffany, S. T. and Drobes, D. J. (1991) The development and initial validation of a questionnaire on smoking urges. British Journal of Addiction, 86, pp. 1467-1476.
45. Warner, K. E. (2002) Tobacco harm reduction: Promise and perils. Nicotine & Tobacco Research, 4((Suppl.2)), pp. S61-S71.
46. Zacny, J. P. and Stitzer, M. L. (1988) Cigarette brand-switching: Effects on smoke exposure and smoking behavior. The Journal of Pharmacology and Experimental Therapeutics, 246, pp. 619-627.